## Table 2

|  |  |  |  | Outcome, Q3 v. Q1 | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | Unadjusted | | Fully adjusted | |
| Urinary oxidative stress biomarker | Outcome | Q1 Mean | Q3 Mean | Coefficient (95% CI) | P-value | Coefficient (95% CI) | P-value |
| IPF(2a)-III | LAZ Year 1 | 0.48 | 0.91 | -0.12 (-0.2, -0.03) | 0.31 | 0 (-0.03, 0.02) | 1.19 |
|  | LAZ Year 2 | 0.48 | 0.92 | -0.06 (-0.12, 0.01) | 1 | 0 (-0.04, 0.04) | 1.05 |
|  | Length velocity Year 1 and Year 2 | 0.48 | 0.92 | 0 (-0.01, 0.01) | 0.86 | 0 (0, 0.01) | 0.28 |
|  | Change in LAZ Year 1 to Year 2 | 0.48 | 0.92 | 0.03 (0, 0.07) | 0.06 | 0.01 (-0.02, 0.04) | 0.46 |
|  |  |  |  |  |  |  |  |
| 2,3-dinor-iPF(2a)-III | LAZ Year 1 | 4.7 | 7.14 | -0.25 (-0.33, -0.16) | 0 | 0 (-0.03, 0.04) | 0.8 |
|  | LAZ Year 2 | 4.67 | 7.16 | -0.15 (-0.24, -0.06) | 0.15 | -0.01 (-0.07, 0.05) | 1.27 |
|  | Length velocity Year 1 and Year 2 | 4.67 | 7.16 | 0.01 (-0.02, 0.03) | 0.64 | 0.01 (0, 0.03) | 0.08 |
|  | Change in LAZ Year 1 to Year 2 | 4.67 | 7.16 | 0.08 (0.01, 0.16) | 0.04 | 0.02 (-0.05, 0.09) | 0.63 |
|  |  |  |  |  |  |  |  |
| iPF(2a)-VI | LAZ Year 1 | 10.05 | 17.63 | -0.39 (-0.65, -0.14) | 0.2 | -0.04 (-0.14, 0.05) | 1.36 |
|  | LAZ Year 2 | 9.95 | 17.51 | -0.09 (-0.18, 0) | 0.87 | 0.01 (-0.03, 0.05) | 0.54 |
|  | Length velocity Year 1 and Year 2 | 9.95 | 17.51 | 0 (-0.01, 0.01) | 0.55 | 0.01 (0, 0.02) | 0.04 |
|  | Change in LAZ Year 1 to Year 2 | 9.95 | 17.51 | 0.15 (0.06, 0.25) | 0 | 0.06 (-0.01, 0.14) | 0.11 |
|  |  |  |  |  |  |  |  |
| 8,12-iso-iPF(2a)-VI | LAZ Year 1 | 8.7 | 18.43 | 0.07 (-0.18, 0.32) | 0.61 | 0.03 (-0.01, 0.06) | 0.11 |
|  | LAZ Year 2 | 8.72 | 18.23 | 0.07 (-0.13, 0.26) | 0.53 | 0.01 (-0.17, 0.19) | 0.95 |
|  | Length velocity Year 1 and Year 2 | 8.72 | 18.23 | 0.01 (-0.01, 0.03) | 0.39 | 0.01 (-0.01, 0.03) | 0.2 |
|  | Change in LAZ Year 1 to Year 2 | 8.72 | 18.23 | 0.09 (-0.01, 0.18) | 0.08 | 0.05 (-0.03, 0.14) | 0.22 |

## Table 3

|  |  |  |  | Outcome, Q3 v. Q1 | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | Unadjusted | | Fully adjusted | |
| Salivary stress biomarker | Outcome | Q1 Mean | Q3 Mean | Coefficient (95% CI) | P-value | Coefficient (95% CI) | P-value |
| Pre to post-stress change in cortisol | LAZ Year 2 | -0.01 | 0 | 0.01 (-0.08, 0.09) | 0.83 | -0.06 (-0.2, 0.08) | 1.36 |
|  |  |  |  |  |  |  |  |
| Cortisol residualized gain score | LAZ Year 2 | -0.21 | 0.14 | 0 (-0.09, 0.08) | 1.03 | 0.06 (-0.04, 0.17) | 0.22 |
|  |  |  |  |  |  |  |  |
| Pre to post-stress change in sAA | LAZ Year 2 | -4.37 | 0.06 | -0.04 (-0.28, 0.19) | 1.23 | -0.01 (-0.04, 0.03) | 1.21 |
|  |  |  |  |  |  |  |  |
| sAA residualized gain score | LAZ Year 2 | -51.35 | 27.2 | -0.01 (-0.25, 0.23) | 1.04 | 0.05 (-0.03, 0.13) | 0.19 |

## Table 4

|  |  |  |  | Outcome, Q3 v. Q1 | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | Unadjusted | | Fully adjusted | |
| Resting SAM biomarker | Outcome | Q1 Mean | Q3 Mean | Coefficient (95% CI) | P-value | Coefficient (95% CI) | P-value |
| Mean arterial pressure | LAZ Year 2 | 60.89 | 68.89 | 0.13 (0, 0.25) | 0.05 | -0.01 (-0.07, 0.06) | 1.14 |
|  |  |  |  |  |  |  |  |
| Mean resting heart rate | LAZ Year 2 | 98.5 | 118 | -0.15 (-0.3, -0.01) | 0.77 | 0 (-0.07, 0.07) | 1.08 |

## Table 5

|  |  |  |  | Outcome, Q3 v. Q1 | | | |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  | Unadjusted | | Fully adjusted | |
| Methylation site | Outcome | Q1 Mean | Q3 Mean | Coefficient (95% CI) | P-value | Coefficient (95% CI) | P-value |
| Entire promoter region (39 assayed CpG sites) | LAZ Year 2 | 0.22 | 0.48 | -0.05 (-0.11, 0.01) | 1.15 | -0.02 (-0.06, 0.02) | 1.36 |
|  |  |  |  |  |  |  |  |
| NGFI-A transcription factor binding site (CpG site #12) | LAZ Year 2 | 0 | 1.21 | 0.16 (-0.08, 0.4) | 0.2 | 0.02 (-0.05, 0.08) | 0.63 |